Advanced search
Publication Cover
Leukemia & Lymphoma Volume 62, 2021 - Issue 8
Submit an article Journal homepage
454
Views
3
CrossRef citations to date
0
Altmetric
Letters to the Editor

The safety and efficacy of dasatinib plus nivolumab in patients with previously treated chronic myeloid leukemia: results from a phase 1b dose-escalation study

Joaquín Martínez-Lópeza Servicio de Hematología y Hemoterapia, Hospital Universitario 12 de Octubre, CNIO, Universidad Complutense de Madrid (UCM), Madrid, SpainCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-7908-0063View further author information
ORCID Icon,
Satu Mustjokib Translational Immunology Research Program and Department of Clinical Chemistry and Hematology, University of Helsinki, Helsinki, Finland;c Hematology Research Unit Helsinki, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki, FinlandORCID Iconhttps://orcid.org/0000-0002-0816-8241View further author information
ORCID Icon,
Kimmo Porkkac Hematology Research Unit Helsinki, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki, FinlandView further author information
,
Rebecca B. Klisovicd Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USAView further author information
,
Dominik Wolfe Internal Medicine V, Hematology and Oncology, Medical University of Innsbruck, Innsbruck, Austria;f Medical Clinic 3, University Hospital Bonn, Bonn, GermanyView further author information
,
Lambert Busqueg Department of Hematology, Maisonneuve-Rosemont Hospital, Montreal, QC, Canada;h Department of Medicine, University of Montreal, Montreal, QC, CanadaView further author information
,
Juan Carlos Hernández-Boludai Hematology Department, Hospital Clínico Universitario Valencia, University of Valencia, Valencia, SpainORCID Iconhttps://orcid.org/0000-0002-4289-3113View further author information
ORCID Icon,
Rene Swaninkj Bristol Myers Squibb, Princeton, NJ, USAView further author information
,
Patricia Martin Regueiraj Bristol Myers Squibb, Princeton, NJ, USAView further author information
&
Jeffrey H. Liptonk Princess Margaret Cancer Centre, Toronto, ON, CanadaView further author information
 show all
Pages 2040-2043 | Received 18 Aug 2020, Accepted 06 Feb 2021, Published online: 02 Mar 2021

References

  • Gambacorti-Passerini C, Aroldi A, Cordani N, et al. Chronic myeloid leukemia: second-line drugs of choice. Am J Hematol. 2016;91(1):67–75.
  • Garg RJ, Kantarjian H, O’Brien S, et al. The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up. Blood. 2009;114(20):4361–4368.
  • Jabbour EJ, Cortes JE, Kantarjian HM. Resistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment options. Clin Lymphoma Myeloma Leuk. 2013;13(5):515–529.
  • Guilhot F, Lacotte-Thierry L. Interferon-alpha: mechanisms of action in chronic myelogenous leukemia in chronic phase. Hematol Cell Ther. 1998;40(5):237–239.
  • Barrett J. Allogeneic stem cell transplantation for chronic myeloid leukemia. Semin Hematol. 2003;40(1):59–71.
  • Or R, Shapira MY, Resnick I, et al. Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase. Blood. 2003;101(2):441–445.
  • Christiansson L, Soderlund S, Svensson E, et al. Increased level of myeloid-derived suppressor cells, programmed death receptor ligand 1/programmed death receptor 1, and soluble CD25 in Sokal high risk chronic myeloid leukemia. PLoS One. 2013;8(1):e55818.
  • Mumprecht S, Schurch C, Schwaller J, et al. Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression. Blood. 2009;114(8):1528–1536.
  • Bruck O, Blom S, Dufva O, et al. Immune cell contexture in the bone marrow tumor microenvironment impacts therapy response in CML. Leukemia. 2018;32(7):1643–1656.
  • Hughes A, Clarson J, Tang C, et al. CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors. Blood. 2017;129(9):1166–1176.
  • Mustjoki S, Ekblom M, Arstila TP, et al. Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia. 2009;23(8):1398–1405.
  • Schiffer CA, Cortes JE, Hochhaus A, et al. Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: effects on response and toxicity. Cancer. 2016;122(9):1398–1407.
  • Kreutzman A, Ladell K, Koechel C, et al. Expansion of highly differentiated CD8+ T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation. Leukemia. 2011;25(10):1587–1597.
  • Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122(6):872–884.
  • Vardhana S, Cicero K, Velez MJ, et al. Strategies for recognizing and managing immune-mediated adverse events in the treatment of Hodgkin lymphoma with checkpoint inhibitors. Oncologist. 2019;24(1):86–95.
  • Choi J, Lee SY. Clinical characteristics and treatment of immune-related adverse events of immune checkpoint inhibitors. Immune Netw. 2020;20(1):e9.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.